Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Court Suggests Abbott Lawyer Cheated on Hytrin Patent
- A federal appeals court has strongly suggested that an "Abbott in-house attorney" is a cheat. In a ruling on whether Abbott Labs broke antitrust law in consipiring with generic makers to keep Hytrin, a hypertension and prostate enlargement drug, off the market, the judges described why they were sending the ...
- Blog posts 2009-01-26
Additional Resources
- FTC charges drug manufacturers with stifling competition in two prescription drug markets; Complaint filed against Hoechst Marion Roussel, Inc. and Andrx Corp.; Proposed settlement reached with Abbott Laboratories and Geneva Pharmaceuticals, Inc.
- M2 PRESSWIRE-17 March 2000-US FTC: FTC charges drug manufacturers with stifling competition in two prescription drug markets; Complaint filed against Hoechst Marion Roussel, Inc. and Andrx Corp.; Proposed settlement reached with Abbott Laboratories and Geneva Pharmaceuticals, Inc. C1994-2000 M2 COMMUNICATIONS LTD ...
- Research articles 2000-03-17
- FTC chides Abbott Lab for generic drug deal.(Business)
- Abbott Laboratories received a scolding from the U.S. Federal Trade Commission on Thursday for paying another drug maker to keep a generic version of its hypertension drug, Hytrin, off the market. The consent order approved by the commission Thursday includes no financial penalties for...
- Research articles 2000-03-17
- Abbott Labs Q1: Has the Company Taken Its Eye Off the Sales Force Ball?
- Abbott Labs' stock took a beating today even though it posted a 53 percent gain in net income, to $1.4 billion. Investors didn't like that $1 billion of that profit came from a one-off item reflecting the end of a joint venture with TAP. Revenues were flat at $6.7 billion....
- Blog posts 2009-04-15
- << Previous
- page 1 of 1
- Next >>
